Note: This document has been translated from the Japanese original for reference purposes only. In the event of any
discrepancy between this translated document and the Japanese original, the original shall prevail.

Consolidated Financial Results for the First Quarter of FY2024(from April 1, 2024 to March 31, 2025)<Based on Japanese GAAP>
ASKA Pharmaceutical Holdings Co., Ltd.
Tokyo
4886
URL https://www.aska-pharma-hd.co.jp/english/
President and Representative Director
Takashi Yamaguchi
Inquiries：
Corporate Planning Department Director
Hideaki Kobayashi
Scheduled date to commence dividend payments：
Preparation of supplementary material on financial results：
Yes
Holding of financial results meeting：No

August 5, 2024

Company name:
Stock exchange listing:Stock code:
Representative：

TEL +81-3-5484-8366(Amounts less than one million yen are rounded down)
1. Consolidated financial results for the First quarter of FY2024 (from April 1, 2024 to June 30, 2024)(1) Consolidated operating results
Percentages indicate year-on-year changes
Profit attributable to
Net sales
Operating profit
Ordinary profit
owners of parent
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
First quarter of FY2024
16,352
2.1
1,758
3.1
1,813
0.2
1,273 (10.9)
First quarter of FY2023
16,023
4.9
1,704
2.4
1,809
0.2
1,428
8.0
Note: Comprehensive income
First quarter of FY2024(Millions of yen)
1,965
(23.3) %First quarter of FY2023(Millions of yen)
2,563
43.0%
Earnings per share
Yen
44.95
50.51

First quarter of FY2024
First quarter of FY2023(2) Consolidated financial position

As of June 30, 2024
As of March 31, 2024
Reference: Tangible net worth

Diluted earnings per
share
Yen
－
－

Total assets
Millions of yen
87,32190,745

Net assets
Millions of yen
63,32961,930

As of June 30, 2024

(Millions of yen)

63,329As of March 31, 2024

(Millions of yen)

61,9302. Cash dividends
1st quarter-end
Yen-

Equity ratio
%
72.5
68.2

Annual dividends per share
2nd quarter-end 3rd quarter-end Fiscal year-end
Yen
Yen
Yen
－
20.00
20.00

Year ended March 31, 2024
Year ending March 31, 2025
Year ending March 31, 2025
25.00
(Forecast)
Note: Revision from dividend forecast currently announced: No

－

25.00

Total

Yen
40.00
50.00

3. Forecast of consolidated financial results for FY2024 (from April 1, 2024 to March 31, 2025)
Percentages indicate year-on-year changes
Net sales
Full year

Millions of yen
63,000Operating profit% Millions of yen
0.2
6,700

Ordinary profit% Millions of yen
3.1
6,700

Note: Revision from dividend forecast currently announced: No

Profit attributable toowners of parent

Earnings per share% Millions of yen%
2.7
5,000 (33.7)

Yen
176.50Notes:(1) Significant changes in the scope of consolidation during the period:
Newly included: -, Excluded: -No(2) Application of special accounting methods for preparing quarterly consolidated financial statements:

No(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements
Changes in accounting policies due to revisions to accounting standards and other regulations:No

Changes in accounting policies due to other reasons:No

Changes in accounting estimates:

No

Restatement of prior period financial statements:

No(4) Number of shares issued (ordinary shares)
1) Total number of shares issued at the end of the period (including treasury shares)
As of June 30, 2024

30,563,199

As of March, 2023

30,563,199

As of March, 2023

2,233,957

2) Number of treasury shares at the end of the period
As of June 30, 2024

2,234,023

3) Average number of shares during the period (cumulative from the beginning of the fiscal year)
First quarter of FY2024

28,329,194

First quarter of FY2023

28,286,941* Review of the accompanying quarterly consolidated financial statements by a certified public accountant or auditing firm: None
* Explanation concerning appropriate use of projections of business results and other notes
Projections of business results and other forward-looking statements contained in this document are based on assumptions
judged to be reasonable and information currently available to the Company, and the Company does not in any way guarantee
the achievement of the projections. Actual business results may materially differ from the forecasted figures due to various
factors in the future. Please refer to "1. Qualitative Information on Quarterly Financial Results, (3) Description of Forward-looking
Information such as Forecasts of Consolidated Financial Results" for the assumptions used in forecasting business results andprecautions regarding the use of business results forecasts.

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024

CONTENTS
1.

2.

3.

Qualitative Information on Quarterly Financial Results……………………………………………………………….
(1) Description of Operating Results……………………………………………………………………………………

22(2) Description of Financial Position…..………………………………………………………………………………..
(3) Description of Forward-looking Information such as Forecasts of Consolidated Financial Results…..……..

3
3(4) Description of Research and Development…..……………………………………………………………………
Quarterly Consolidated Financial Statements ...………………………………………………………………………

3
4(1) Quarterly Consolidated Balance Sheets…..……………………………………………………………………….
(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive
Income…………………………………………………………………………………………………………………
Quarterly Consolidated Statements of Income
First quarter of the consolidated fiscal year………………………………………………………………………
Quarterly Consolidated Statements of Comprehensive Income
First quarter of the consolidated fiscal year……………………………………………………………………..
(3) Notes to the Quarterly Consolidated Financial Statements……...………………………………………………
(Notes concerning the going-concern assumption) ………………………………………………………………
(Significant changes in the amount of shareholders' equity)………………………………………………..……

4(Notes to Cash Flows)………………………………………………………………..………………………………
(Segment Information)…....……………………………………………………………………………….…………

7
8

Supplemental Material……………………………………………………………………………………………………
(1) Sales of Main Products of the Business Companies……...………………….………………………..…………

9
9

- 1 -

5
6
6
7
7
7

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024

1. Qualitative Information on Quarterly Financial Results(1) Description of Operating Results
During the first quarter of the consolidated fiscal year, despite a gradual return to normal in economic activities, future
prospects remained uncertain as a result of factors such as due to the ongoing geopolitical risks, decreased value ofthe yen on international currency markets and rising prices of energy and raw materials. Even under such conditions,however, the favorable trend in the Group's businesses continued from the previous fiscal year. Thus, both sales andprofit increased from the same period of the previous year. However, the Group's business grew due to the growth ofthe pharmaceutical business and veterinary pharmaceutical business, resulting in net sales of 16,352 million yen (up2.1% YoY), an increase of 329 million yen from the same period of the previous fiscal year. On the profit front, operating
profit increased to 1,758 million yen (up 3.1% YoY) and ordinary profit rose to 1,813 million yen (up 0.2% YoY) due tocost improvement efforts despite an increase in R&D and other expenses. On the other hand, profit attributable toowners of parent was 1,273 million yen (down 10.9% YoY), down 155 million yen from the same period of the previous
year, due to an increase in income taxes as well as reaction to the recording of a gain on sales of investment securities
as extraordinary income in the previous year.
Operating Results during the first quarter of the consolidated fiscal year are described below.
First quarter ofFirst quarter of
FY2023
FY2024
ActualConsolidated
Consolidated
Cumulative Period
Cumulative Period(Millions of yen)
(Millions of yen)
(Millions of yen)

Growth(%)

Net sales

16,023

16,352329

2.1

Operating profit

1,704

1,758

53

3.1

Ordinary profit

1,809

1,813

3

0.2

Profit attributable toowners of parent

1,428

1,273

(155)

(10.9)

Business results by segment are described below.
(i) Pharmaceutical business
The pharmaceutical business, which focuses on the three fields of internal medicine, obstetrics and gynecology, andurology, showed favorable trends overall despite the impact of the periodical NHI drug price revisions. A look at results
by product shows that results in the obstetrics and gynecology area were driven by the growth in the uterine fibroidand endometriosis agent RELUMINA (relugolix), to 2,644 million yen (up 2.6% YoY). In addition to these, sales of thedysmenorrhea agent DroEthi (drospirenone/ ethinylestradiol) increased significantly to 1,743 million yen (up 24.5%
YoY), following the previous year. In the internal medicine area, sales of the thyroid hormone agent THYRADIN(levothyroxine), our main product in this field, grew to 2,076 million yen (up 0.7% YoY) and those of the poorly
absorbable rifamycin antimicrobial agent RIFXIMA (rifaximin) increased to 1,645 million yen (up 7.9% YoY). In theurology field, sales of the LH-RH derivative microcapsule sustained-release agent LEUPRORELIN were 1,021 million
yen (down 14.3% YoY).
As a result of the above factors, the segment sales were 14,493 million yen (up 0.5% YoY), and the segment profit
was 2,012 million yen (down 0.5% YoY).
(ii) Animal health business
Sales of the animal health business, which sells products such as veterinary pharmaceuticals and feed additives,
were 1,800 million yen (up 15.4% YoY). The segment profit was 73 million yen (vs. a loss of 1 million yen in the same
period of the previous year).
(iii) Other businesses
Sales of the other businesses, which include clinical testing, medical devices, etc., were 57 million yen (up 37.6%
YoY). However, the segment loss was 5 million yen (vs. a loss of 27 million yen in the same period of the previousyear).
* For sales of main products, please refer to 3. Supplemental Material.

- 2 -ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024(2) Description of Financial Position(Assets)
Total assets at the end of the first quarter of the consolidated fiscal year under review stood at 87,321 million yen,down 3,423 million yen from the end of the previous consolidated fiscal year under review. This figure was due
primarily to decreases in cash and deposits, and securities.
(Liabilities)
Total liabilities at the end of the first quarter of the consolidated fiscal year under review stood at 23,992 million yen,down 4,822 million yen from the end of the previous consolidated fiscal year. This figure was due primarily todecreases in other in current liabilities, short-term borrowings and long-term borrowings.
(Net assets)
Total assets at the end of the first quarter of the consolidated fiscal year under review stood at 63,329 million yen, up
1,398 million yen from the end of the previous consolidated fiscal year. This figure was due primarily to an increase
in retained earnings resulting from the recording of profit attributable to owners of parent and an increase in valuationdifference on available-for-sale securities reflecting rising share prices.
The resulting equity ratio was 72.5%, up 4.3 percentage points from the end of the previous consolidated fiscal year.
(3) Description of Forward-looking Information such as Forecasts of Consolidated Financial Results
Forecasts of consolidated financial results for FY2024 are unchanged from the full-year consolidated performance
forecasts in the “Summary of Consolidated Financial Results for FY2024 (from April 1, 2023 to March 31, 2024),”
published on May 10, 2024.
(4) Description of Research and Development
R&D expenses during the first quarter of the consolidated fiscal year under review stood at 1,652 million yen.

- 3 -ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024

2.

Quarterly Consolidated Financial Statements(1) Quarterly Consolidated Balance Sheets(Millions of yen)
As of March 31, 2024

AssetsCurrent assets
Cash and deposits
Accounts receivable - trade
Securities
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Total current assets
Non-current assets
Property, plant and equipment
Intangible assets
Investments and other assets
Investment securities
Other
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets
Liabilities
Current liabilities
Accounts payable - trade
Electronically recorded obligations - operating
Short-term borrowings
Other provisions
Other
Total current liabilities
Non-current liabilities
Long-term borrowings
Retirement benefit liability
Other
Total non-current liabilities
Total liabilities
Net assets
Shareholders' equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-salesecurities
Foreign currency translation adjustment
Remeasurements of defined benefit plans
Total accumulated other comprehensive
incomeTotal net assets
Total liabilities and net assets- 4 -As of June 30, 2024

13,73815,5793,500
12,578
466
7,358
2,922
56,143

12,024
14,9782,000
12,020
351
8,129
2,495
52,00011,263
2,877

11,704
3,403

15,6544,823(17)
20,461
34,60190,745

16,6013,629(17)
20,21335,321
87,321

4,060
3,295
4,980
1,226
10,40523,968

4,216
2,686
4,180
588
7,872
19,542

4,505
－
341
4,846
28,815

4,085
20
343
4,449
23,992

1,197
1,848
56,372(3,287)56,1301,197
1,848
57,079(3,287)
56,837

4,790

5,317

424
584

606
568

5,799

6,492

61,93090,74563,32987,321

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024(2) Quarterly Consolidated Statements of Income and Quarterly Consolidated Statements of Comprehensive Income(Quarterly Consolidated Statements of Income)(First quarter of the consolidated fiscal year)(Millions of yen)Three months ended
June 30, 2023
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit
Non-operating income
Interest income
Dividend income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity
methodLoss on investments in investment partnerships
Expenses of inactive non-current assets
Other
Total non-operating expenses
Ordinary profit
Extraordinary income
Gain on sale of investment securities
Total extraordinary income
Profit before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
ProfitProfit attributable to owners of parent- 5 -Three months ended
June 30, 2024

16,023
8,559
7,463
5,759
1,704

16,352
8,181
8,171
6,413
1,758

0
178
19
197

0
137
16
154

11

11

－

31

－
35
46
93
1,809

21
4
30
99
1,813

64
64
1,873
346
98
444
1,428
1,428

－
－
1,813
133
406
539
1,273
1,273

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024(Quarterly Consolidated Statements of Income)(First quarter of the consolidated fiscal year)(Millions of yen)Three months ended
June 30, 2023
ProfitOther comprehensive income
Valuationdifferenceonavailable-for-salesecurities
Remeasurements of defined benefit plans, net oftax
Share of other comprehensive income of entities
accounted for using equity method
Total other comprehensive income
Comprehensive income
Comprehensive income attributable toComprehensive income attributable to owners ofparent- 6 -Three months ended
June 30, 2024

1,428

1,273

1,076

526

(7)

(16)

66

181

1,135
2,563

692
1,965

2,563

1,965

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024(3) Notes to the Quarterly Consolidated Financial Statements(Notes concerning the going-concern assumption)
Not applicable.
(Significant changes in the amount of shareholders' equity)
Not applicable.
(Notes to Cash Flows)
Quarterly consolidated statements of cash flows for the first quarter of the current fiscal year have not been prepared.
Depreciation (including amortization related to intangible assets excluding goodwill) for the first quarter of the current
fiscal year is as follows.

(Millions of yen)Three months ended
June 30, 2023

Depreciation

679

- 7 -

Three months ended
June 30, 2024
499

ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024(Notes to Segment Information)[Segment information]
I. Previous first quarter of the consolidated fiscal year (from April 1, 2023 to June 30, 2023)
Net sales and profit or loss by reportable segment

Reporting-segment
Pharmaceutical Animal healthbusinessbusiness

Others
Note 1.

(Millions of yen)Amountrecorded on
Amounts ofconsolidated
adjustments
financial
Note 2.
statements

Total

Note 3.

Net Sales
Sales to externalcustomers
Intersegment sales
and transfers

14,4201,560

42

16,023－16,023

－

－

13

13

(13)

－

Total

14,4201,560

55

16,036(13)

16,023

Segment profit/loss

2,021

(1)

(27)

1,993

(288)

1,704

Notes:
1. The “Other” business segment consists of businesses not included in the reportable segments,
including clinical testing and medical devices, etc.
2. The adjustment of (288) million yen to segment profit or loss (numbers in parentheses) consists ofcompanywide expenses not allocated to individual business segments, which consist mainly ofgeneral and administrative expenses not attributable to business segments.
3. Segment profit or loss (numbers in parentheses) is adjusted against operating profit on the quarterly
consolidated statements of income.
II.

Current first quarter of the consolidated fiscal year (from April 1, 2024 to June 30, 2024)
1 Net sales and profit or loss by reportable segment(Millions of yen)
Reporting-segment
Pharmaceutical Animal healthbusinessbusiness

Others
Note 1.

Amountrecorded on
Amounts ofconsolidated
adjustments
financial
Note 2.
statements

Total

Note 3.

Net Sales
Sales to externalcustomers
Intersegment sales
and transfers

14,4931,800

57

16,352－

16,352

－

－

16

16

(16)

－

Total

14,4931,800

74

16,369(16)

16,352

Segment profit/loss

2,012

73

(5)

2,079

(321)

1,758

Notes:
1. The “Other” business segment consists of businesses not included in the reportable segments,
including clinical testing and medical devices, etc.
2. The adjustment of (321) million yen to segment profit or loss (numbers in parentheses) consists ofcompanywide expenses not allocated to individual business segments, which consist mainly ofgeneral and administrative expenses not attributable to business segments.
3. Segment profit or loss (numbers in parentheses) is adjusted against operating profit on the quarterly
consolidated statements of income.

- 8 -ASKA Pharmaceutical Holdings Co., Ltd. (securities code: 4886) Consolidated Financial Results for the First Quarter of FY2024

3.

Supplemental Material(1) Sales of Main Products of the Business Companies
S a l e s
(

F

Y

2

o f
0

2

M a i n4

1

P r o d u c t s

Q

A

c

t

u

a

l

)

ASKA Pharmaceutical Co., Ltd.

(Millions of yen)
FY2024FY2023
Therapeutic category

Products

1Q
ActualFY2023
Actual

1Q
ActualFY2024
Forecast

1Q Actual
YOY(%)

Uterine fibroid andendometriosis agent

RELUMINA(relugolix)

2,576

9,906

2,644

10,945

2.6

Antihypertensive agent

CANDESARTAN*(candesartan)

2,599

9,593

2,230

8,447

(14.2)

Thyroid hormone agent

THYRADIN(levothyroxine)

2,062

7,862

2,076

8,018

0.7

Dysmenorrhea agent

DroEthi(drospirenone/
ethinylestradiol)

1,401

6,125

1,743

6,416

24.5

Poorly absorbable rifamycin
antimicrobial agent

RIFXIMA(rifaximin)

1,525

5,864

1,645

6,117

7.9

LH-RH derivative
microcapsule sustainedrelease agent

LEUPRORELIN(leuprorelin)

1,192

4,430

1,021

3,962

(14.3)

Dysmenorrhea agent

FREWELL(norethisterone/
ethinylestradiol)

832

3,303

771

3,101

(7.4)

Progesterone hormone agent

LUTEUM(progesterone)

440

2,029

556

2,171

26.3

Antithyroid agent

MERCAZOLE(thiamazole)

398

1,521

403

1,510

1.2

Antihypertensive agent

AMLODIPINE(amlodipine)

225

840

209

806

(7.3)

* Including compounding agents

ASKA Animal Health Co., Ltd.

(Millions of yen)
FY2024FY2023Business field

1Q
ActualFY2023
Actual

1Q
Actual

1Q Actual

FY2024
Forecast

YOY(%)

Feed additives, mixed feed, and feed materials

965

4,042

1,160

4,031

20.2

Veterinary pharmaceuticals

576

2,487

625

2,534

8.5

- 9 -